Factors associated with pharyngoesophageal stricture in patients treated with concurrent chemotherapy and radiation therapy for oropharyngeal squamous cell carcinoma.
BACKGROUND
The purpose of this study was to elucidate factors associated with pharyngoesophageal strictures after treatment for head and neck squamous cell carcinoma (SCC).


METHODS
We conducted a retrospective review of patients receiving cisplatin and 5-fluorouracil chemotherapy combined with concurrent hyperfractionated radiation therapy for oropharyngeal squamous cell carcinoma.


RESULTS
Strictures developed in 13 of 67 patients (19%). Strictures were associated with tumor location (tonsil vs base of tongue; p = .03), neck dissection after completion of therapy (p = .03), and the duration of treatment-induced mucositis (weeks with mucositis grade ≥2; National Cancer Institute (NCI) Common Toxicity Criteria; p < .001). Age, sex, race, tumor stage, nodal stage, American Joint Committee on Cancer (AJCC) stage, human papillomavirus (HPV) status, smoking, radiation dose, maximum severity of mucositis, amifostine use, and pretreatment swallow dysfunction were not significantly associated with stricture. In multivariate analysis, only duration of mucositis, after controlling for age, sex, and tumor location, remained highly significant (p < .01).


CONCLUSIONS
The duration of treatment-related mucositis is an independent risk factor for stricture formation in patients with oropharyngeal SCC treated with concurrent chemotherapy and radiation therapy.
Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins Medical Institution, Baltimore, Maryland, USA.
Simon R
SR
Best
Patrick K
PK
Ha
Ray G
RG
Blanco
John R
JR
Saunders
Eva S
ES
Zinreich
Marshall A
MA
Levine
Sara I
SI
Pai
Melissa
M
Walker
Jaclyn
J
Trachta
Karen
K
Ulmer
Peter
P
Murakami
Richard
R
Thompson
Joseph A
JA
Califano
Barbara P
BP
Messing
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003251:Constriction, Pathologic; D019583:Dose Fractionation, Radiation; D004940:Esophageal Stenosis / Q000209:etiology*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009959:Oropharyngeal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D010608:Pharyngeal Diseases / Q000209:etiology*; D011832:Radiation Injuries; D013280:Stomatitis / Q000209:etiology
D002945:Cisplatin; D005472:Fluorouracil
J Clin Oncol. 2009 Sep 10;27(26):4333-8
19636011
Head Neck. 2010 Mar;32(3):341-7
19693946
N Engl J Med. 1998 Jun 18;338(25):1798-804
9632446
J Pain Symptom Manage. 2009 Oct;38(4):522-32
19608377
Biologics. 2009;3:111-6
19707400
Int J Cancer. 2009 Nov 1;125(9):2159-65
19569190
Int J Radiat Oncol Biol Phys. 2010 Feb 1;76(2):403-9
19467801
J Clin Oncol. 2003 Jan 1;21(1):92-8
12506176
Cancer. 2009 Oct 1;115(19):4514-23
19634161
Cancer. 2002 Feb 15;94(4):1131-41
11920484
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1110-8
18468812
J Natl Cancer Inst. 1999 Dec 15;91(24):2081-6
10601378
N Engl J Med. 2007 May 10;356(19):1944-56
17494927
Arch Otolaryngol Head Neck Surg. 2009 Dec;135(12):1225-30
20026820
Cancer. 2001 May 1;91(9):1785-90
11335904
Laryngoscope. 2009 Aug;119(8):1542-9
19522004
N Engl J Med. 2003 Nov 27;349(22):2091-8
14645636
Semin Oncol. 2004 Dec;31(6 Suppl 18):2-7
15726515
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000978
17943748
Head Neck. 2006 Sep;28(9):808-12
16732601
Cancer. 2008 Nov 15;113(10 Suppl):2901-9
18980273
J Natl Cancer Inst. 2008 Feb 20;100(4):261-9
18270337
Anticancer Res. 2009 May;29(5):1467-74
19443352
J Clin Oncol. 2008 Jul 20;26(21):3582-9
18559875
Arch Otolaryngol Head Neck Surg. 2007 Dec;133(12):1220-6
18086963
Cancer. 2006 Jan 15;106(2):329-36
16342066